Three Months’ PSA and Toxicity from a Prospective Trial Investigating STereotactic sAlvage Radiotherapy for Macroscopic Prostate Bed Recurrence after Prostatectomy—STARR (NCT05455736)
Biochemical recurrences after radical prostatectomy (RP) can be managed with curative purpose through salvage radiation therapy (SRT). RT dose escalation, such as stereotactic RT (SSRT), may improve relapse-free survival in this setting. STARR trial (NCT05455736) is a prospective multicenter study i...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/3/992 |
| _version_ | 1797624969725739008 |
|---|---|
| author | Giulio Francolini Pietro Garlatti Vanessa Di Cataldo Beatrice Detti Mauro Loi Daniela Greto Gabriele Simontacchi Ilaria Morelli Luca Burchini Andrea Gaetano Allegra Giulio Frosini Michele Ganovelli Viola Salvestrini Emanuela Olmetto Luca Visani Carlotta Becherini Marianna Valzano Maria Grazia Carnevale Manuele Roghi Sergio Serni Chiara Mattioli Isacco Desideri Lorenzo Livi |
| author_facet | Giulio Francolini Pietro Garlatti Vanessa Di Cataldo Beatrice Detti Mauro Loi Daniela Greto Gabriele Simontacchi Ilaria Morelli Luca Burchini Andrea Gaetano Allegra Giulio Frosini Michele Ganovelli Viola Salvestrini Emanuela Olmetto Luca Visani Carlotta Becherini Marianna Valzano Maria Grazia Carnevale Manuele Roghi Sergio Serni Chiara Mattioli Isacco Desideri Lorenzo Livi |
| author_sort | Giulio Francolini |
| collection | DOAJ |
| description | Biochemical recurrences after radical prostatectomy (RP) can be managed with curative purpose through salvage radiation therapy (SRT). RT dose escalation, such as stereotactic RT (SSRT), may improve relapse-free survival in this setting. STARR trial (NCT05455736) is a prospective multicenter study including patients affected by macroscopic recurrence within the prostate bed after RP treated with SSRT. Recurrence was detected with a Choline or PSMA CT-PET. In the current analysis, the early biochemical response (BR) rate and toxicity profile after three months of follow-up were assessed. Twenty-five patients were enrolled, and data about BR and toxicity at three months after treatment were available for 19 cases. Overall, BR was detected after three months in 58% of cases. Four G1–G2 adverse events were recorded; no G ≥ 3 adverse events were detected. SSRT appears feasible and safe, with more than half of patients experiencing BR and an encouraging toxicity profile. The STARR trial is one of the few prospective studies aimed at implementing this promising treatment strategy in this scenario. |
| first_indexed | 2024-03-11T09:50:12Z |
| format | Article |
| id | doaj.art-86126c9e61c64a91a6f0eff092d46476 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T09:50:12Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-86126c9e61c64a91a6f0eff092d464762023-11-16T16:20:08ZengMDPI AGCancers2072-66942023-02-0115399210.3390/cancers15030992Three Months’ PSA and Toxicity from a Prospective Trial Investigating STereotactic sAlvage Radiotherapy for Macroscopic Prostate Bed Recurrence after Prostatectomy—STARR (NCT05455736)Giulio Francolini0Pietro Garlatti1Vanessa Di Cataldo2Beatrice Detti3Mauro Loi4Daniela Greto5Gabriele Simontacchi6Ilaria Morelli7Luca Burchini8Andrea Gaetano Allegra9Giulio Frosini10Michele Ganovelli11Viola Salvestrini12Emanuela Olmetto13Luca Visani14Carlotta Becherini15Marianna Valzano16Maria Grazia Carnevale17Manuele Roghi18Sergio Serni19Chiara Mattioli20Isacco Desideri21Lorenzo Livi22Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, 50134 Firenze, ItalyRadiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, 50134 Firenze, ItalyRadiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, 50134 Firenze, ItalyRadiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, 50134 Firenze, ItalyRadiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, 50134 Firenze, ItalyRadiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, 50134 Firenze, ItalyRadiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, 50134 Firenze, ItalyDepartment of Biomedical, Experimental and Clinical Sciences “M. Serio”, University of Florence, 50121 Firenze, ItalyDepartment of Biomedical, Experimental and Clinical Sciences “M. Serio”, University of Florence, 50121 Firenze, ItalyDepartment of Biomedical, Experimental and Clinical Sciences “M. Serio”, University of Florence, 50121 Firenze, ItalyDepartment of Biomedical, Experimental and Clinical Sciences “M. Serio”, University of Florence, 50121 Firenze, ItalyDepartment of Biomedical, Experimental and Clinical Sciences “M. Serio”, University of Florence, 50121 Firenze, ItalyCyberKnife Center, Istituto Fiorentino di Cura e Assistenza (IFCA), 50134 Firenze, ItalyRadiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, 50134 Firenze, ItalyCyberKnife Center, Istituto Fiorentino di Cura e Assistenza (IFCA), 50134 Firenze, ItalyRadiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, 50134 Firenze, ItalyDepartment of Biomedical, Experimental and Clinical Sciences “M. Serio”, University of Florence, 50121 Firenze, ItalyDepartment of Biomedical, Experimental and Clinical Sciences “M. Serio”, University of Florence, 50121 Firenze, ItalyDepartment of Biomedical, Experimental and Clinical Sciences “M. Serio”, University of Florence, 50121 Firenze, ItalyDepartment of Urologic Robotic Surgery and Renal Transplantation, Careggi Hospital, University of Florence, 50121 Firenze, ItalyDepartment of Biomedical, Experimental and Clinical Sciences “M. Serio”, University of Florence, 50121 Firenze, ItalyDepartment of Biomedical, Experimental and Clinical Sciences “M. Serio”, University of Florence, 50121 Firenze, ItalyDepartment of Biomedical, Experimental and Clinical Sciences “M. Serio”, University of Florence, 50121 Firenze, ItalyBiochemical recurrences after radical prostatectomy (RP) can be managed with curative purpose through salvage radiation therapy (SRT). RT dose escalation, such as stereotactic RT (SSRT), may improve relapse-free survival in this setting. STARR trial (NCT05455736) is a prospective multicenter study including patients affected by macroscopic recurrence within the prostate bed after RP treated with SSRT. Recurrence was detected with a Choline or PSMA CT-PET. In the current analysis, the early biochemical response (BR) rate and toxicity profile after three months of follow-up were assessed. Twenty-five patients were enrolled, and data about BR and toxicity at three months after treatment were available for 19 cases. Overall, BR was detected after three months in 58% of cases. Four G1–G2 adverse events were recorded; no G ≥ 3 adverse events were detected. SSRT appears feasible and safe, with more than half of patients experiencing BR and an encouraging toxicity profile. The STARR trial is one of the few prospective studies aimed at implementing this promising treatment strategy in this scenario.https://www.mdpi.com/2072-6694/15/3/992radical prostatectomyadjuvant therapylocal invasion |
| spellingShingle | Giulio Francolini Pietro Garlatti Vanessa Di Cataldo Beatrice Detti Mauro Loi Daniela Greto Gabriele Simontacchi Ilaria Morelli Luca Burchini Andrea Gaetano Allegra Giulio Frosini Michele Ganovelli Viola Salvestrini Emanuela Olmetto Luca Visani Carlotta Becherini Marianna Valzano Maria Grazia Carnevale Manuele Roghi Sergio Serni Chiara Mattioli Isacco Desideri Lorenzo Livi Three Months’ PSA and Toxicity from a Prospective Trial Investigating STereotactic sAlvage Radiotherapy for Macroscopic Prostate Bed Recurrence after Prostatectomy—STARR (NCT05455736) Cancers radical prostatectomy adjuvant therapy local invasion |
| title | Three Months’ PSA and Toxicity from a Prospective Trial Investigating STereotactic sAlvage Radiotherapy for Macroscopic Prostate Bed Recurrence after Prostatectomy—STARR (NCT05455736) |
| title_full | Three Months’ PSA and Toxicity from a Prospective Trial Investigating STereotactic sAlvage Radiotherapy for Macroscopic Prostate Bed Recurrence after Prostatectomy—STARR (NCT05455736) |
| title_fullStr | Three Months’ PSA and Toxicity from a Prospective Trial Investigating STereotactic sAlvage Radiotherapy for Macroscopic Prostate Bed Recurrence after Prostatectomy—STARR (NCT05455736) |
| title_full_unstemmed | Three Months’ PSA and Toxicity from a Prospective Trial Investigating STereotactic sAlvage Radiotherapy for Macroscopic Prostate Bed Recurrence after Prostatectomy—STARR (NCT05455736) |
| title_short | Three Months’ PSA and Toxicity from a Prospective Trial Investigating STereotactic sAlvage Radiotherapy for Macroscopic Prostate Bed Recurrence after Prostatectomy—STARR (NCT05455736) |
| title_sort | three months psa and toxicity from a prospective trial investigating stereotactic salvage radiotherapy for macroscopic prostate bed recurrence after prostatectomy starr nct05455736 |
| topic | radical prostatectomy adjuvant therapy local invasion |
| url | https://www.mdpi.com/2072-6694/15/3/992 |
| work_keys_str_mv | AT giuliofrancolini threemonthspsaandtoxicityfromaprospectivetrialinvestigatingstereotacticsalvageradiotherapyformacroscopicprostatebedrecurrenceafterprostatectomystarrnct05455736 AT pietrogarlatti threemonthspsaandtoxicityfromaprospectivetrialinvestigatingstereotacticsalvageradiotherapyformacroscopicprostatebedrecurrenceafterprostatectomystarrnct05455736 AT vanessadicataldo threemonthspsaandtoxicityfromaprospectivetrialinvestigatingstereotacticsalvageradiotherapyformacroscopicprostatebedrecurrenceafterprostatectomystarrnct05455736 AT beatricedetti threemonthspsaandtoxicityfromaprospectivetrialinvestigatingstereotacticsalvageradiotherapyformacroscopicprostatebedrecurrenceafterprostatectomystarrnct05455736 AT mauroloi threemonthspsaandtoxicityfromaprospectivetrialinvestigatingstereotacticsalvageradiotherapyformacroscopicprostatebedrecurrenceafterprostatectomystarrnct05455736 AT danielagreto threemonthspsaandtoxicityfromaprospectivetrialinvestigatingstereotacticsalvageradiotherapyformacroscopicprostatebedrecurrenceafterprostatectomystarrnct05455736 AT gabrielesimontacchi threemonthspsaandtoxicityfromaprospectivetrialinvestigatingstereotacticsalvageradiotherapyformacroscopicprostatebedrecurrenceafterprostatectomystarrnct05455736 AT ilariamorelli threemonthspsaandtoxicityfromaprospectivetrialinvestigatingstereotacticsalvageradiotherapyformacroscopicprostatebedrecurrenceafterprostatectomystarrnct05455736 AT lucaburchini threemonthspsaandtoxicityfromaprospectivetrialinvestigatingstereotacticsalvageradiotherapyformacroscopicprostatebedrecurrenceafterprostatectomystarrnct05455736 AT andreagaetanoallegra threemonthspsaandtoxicityfromaprospectivetrialinvestigatingstereotacticsalvageradiotherapyformacroscopicprostatebedrecurrenceafterprostatectomystarrnct05455736 AT giuliofrosini threemonthspsaandtoxicityfromaprospectivetrialinvestigatingstereotacticsalvageradiotherapyformacroscopicprostatebedrecurrenceafterprostatectomystarrnct05455736 AT micheleganovelli threemonthspsaandtoxicityfromaprospectivetrialinvestigatingstereotacticsalvageradiotherapyformacroscopicprostatebedrecurrenceafterprostatectomystarrnct05455736 AT violasalvestrini threemonthspsaandtoxicityfromaprospectivetrialinvestigatingstereotacticsalvageradiotherapyformacroscopicprostatebedrecurrenceafterprostatectomystarrnct05455736 AT emanuelaolmetto threemonthspsaandtoxicityfromaprospectivetrialinvestigatingstereotacticsalvageradiotherapyformacroscopicprostatebedrecurrenceafterprostatectomystarrnct05455736 AT lucavisani threemonthspsaandtoxicityfromaprospectivetrialinvestigatingstereotacticsalvageradiotherapyformacroscopicprostatebedrecurrenceafterprostatectomystarrnct05455736 AT carlottabecherini threemonthspsaandtoxicityfromaprospectivetrialinvestigatingstereotacticsalvageradiotherapyformacroscopicprostatebedrecurrenceafterprostatectomystarrnct05455736 AT mariannavalzano threemonthspsaandtoxicityfromaprospectivetrialinvestigatingstereotacticsalvageradiotherapyformacroscopicprostatebedrecurrenceafterprostatectomystarrnct05455736 AT mariagraziacarnevale threemonthspsaandtoxicityfromaprospectivetrialinvestigatingstereotacticsalvageradiotherapyformacroscopicprostatebedrecurrenceafterprostatectomystarrnct05455736 AT manueleroghi threemonthspsaandtoxicityfromaprospectivetrialinvestigatingstereotacticsalvageradiotherapyformacroscopicprostatebedrecurrenceafterprostatectomystarrnct05455736 AT sergioserni threemonthspsaandtoxicityfromaprospectivetrialinvestigatingstereotacticsalvageradiotherapyformacroscopicprostatebedrecurrenceafterprostatectomystarrnct05455736 AT chiaramattioli threemonthspsaandtoxicityfromaprospectivetrialinvestigatingstereotacticsalvageradiotherapyformacroscopicprostatebedrecurrenceafterprostatectomystarrnct05455736 AT isaccodesideri threemonthspsaandtoxicityfromaprospectivetrialinvestigatingstereotacticsalvageradiotherapyformacroscopicprostatebedrecurrenceafterprostatectomystarrnct05455736 AT lorenzolivi threemonthspsaandtoxicityfromaprospectivetrialinvestigatingstereotacticsalvageradiotherapyformacroscopicprostatebedrecurrenceafterprostatectomystarrnct05455736 |